MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide and has a poor prognosis. Current treatments for advanced NSCLC included traditional chemotherapy, radiotherapy, targeted therapy, and immunotherapy. The efficacy of targeted therapy relies on oncogene addiction. Mesenchymal-epithelial transition factor (MET) gene can encode unconventional receptor tyrosine kinases with pleiotropic functions, when signals are abnormally activated, it can initiate and maintain tumor transformation, promote cell proliferation, survival, tumor invasion and angiogenesis. Thus, it is a promising therapeutic target. Previous studies have shown that elevated levels of HGF and/or overexpression of c-Met are associated with poor prognosis in lung cancer. In preclinical and clinical trials, c-MET inhibitors have shown some antitumor activity in NSCLC. Although the efficacy results of MET inhibitors in Phase III clinical trials are disappointing, given the molecular heterogeneity of NSCLC, only subgroups of patients with MET gene alterations may benefit from c-MET inhibitors. The challenge for the future is to screen out the potential beneficiaries. To solve this problem, there is need for large data analysis for the detection methods and treatment effects, to establish standards that meet the MET activation status, and determine reliable thresholds to achieve effective patient stratification and clinical decision making. This article summarized the structure of the hepatocyte growth factor (HGF)/c-Met axis, the different mechanisms of MET addiction, as well as MET amplification as acquired resistance mechanism to epidermal growth factor receptor-tyrosine kinase inhibitors, the latest advances of MET inhibitors, and immuotherapy in the treatment of NSCLC with MET alterations.

Introduction

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide.¹ Most patients with NSCLC are diagnosed at an advanced stage, and traditional chemotherapy and radiotherapy have shown limited efficacy.² Although immunotherapy has changed the current state of treatment for NSCLC, many patients do not respond to programmed cell death protein-1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors, especially in patients harboring driven mutations. Small molecule tyrosine kinase inhibitors (TKIs) are now approved for treatment in patients with NSCLC harboring epidermal growth factor receptor (EGFR) mutations, BRAF V600E mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS1 rearrangements; however, all patients will inevitably develop progression of disease.³ Therefore, it is necessary to find new therapeutic targets that drive the pathogenesis of NSCLC and develop more effective targeted drugs.

C-mesenchymal-epithelial transition factor (c-MET), the hepatocyte growth factor (HGF) receptor, is an oncogene encoding tyrosine kinase receptor. It mainly exists in epithelial cells, and plays an important role in embryogenesis, tumor growth, and metastasis.⁴ Once tyrosine kinase receptors are activated by their ligands, mitosis is triggered. This can regulate a variety of cellular functions.^5,6 The dysregulation of MET/HGF axis pathway is involved in the proliferation, survival, invasion, and metastasis of tumor cells.^7,8 This can be found in NSCLC and other solid tumors such as breast cancer, cervical cancer, stomach cancer, and colon cancer.^9,10 C-MET alterations in NSCLC include point mutations, amplification, fusion, and protein overexpression, which are associated with poor prognosis.^11–15 Previous preclinical and clinical studies suggested that MET activation is both a primary oncogenic driver mutation and a secondary driver of acquired resistance to targeted therapy in other genomic subpopulations.¹⁶ Therefore, agents targeting c-MET are a promising treatment strategy for NSCLC. At present, a number of pre-clinical and clinical studies have been conducted on many drugs targeting MET (small molecule TKI, MET antibody, and HGF antibody).^5,17,18 This article reviewed the mechanisms of MET gene addiction, and the clinical application of MET inhibitors in NSCLC.

Dysregulated c-MET Signaling in NSCLC

The c-MET gene is located on chromosome 7 q21-31 belonging to the HGF receptor family, which encodes a protein tyrosine kinase, and regulates important cellular processes including cell differentiation, proliferation, cell cycle, movement, and apoptosis. HGF is a paracrine-signaling molecule that is produced and secreted by mesenchymal cells, which is the only ligand for c-MET.¹⁹ The extracellular portion of c-MET consists of the immunoglobulin (Ig)-like, plexins, transcription factors (IPT) domain, the plexin-semaphorin-integrin (PSI) domain, and the Sema domain (homologous to semaphorin) responsible for binding to HGF. The intracellular portion of c-MET consists of the juxtamembrane (JM) domain, the Catalytic domain, and the Docking site responsible for signal transduction (Figure 1). HGF/c-MET binding leads to receptor dimerization, tyrosine residues autophosphorylate, substrate docking, and activation of downstream signaling pathways such as PI3K/AKT, RAS/ERK/MAPK, Wnt/β-catenin, SRC, and STAT320-29;^20–29 thereby, inducing excessive cell proliferation, and is closely related to the occurrence and development of tumors. It is reported that the deregulation of the MET signaling in NSCLC can induce tumor invasion and metastasis,³⁰ and can interact with other signaling pathways such as EGFR.^31,32

Figure 1.

Major Mechanism of MET/HGF axis dysregulation. The extracellular portion of c-MET consists of a four immunoglobulin (Ig)-like modules, a cysteine-rich, MET-related sequence domain, and a Sema domain (homologous to semaphorin) responsible for binding to HGF. The intracellular portion of c-MET consists of the paramembrane domain, the Catalytic domain, and the Docking site responsible for signal transduction. Various mechanisms of MET/HGF axis addiction in NSCLC, including MET/HGF overexpression, and MET gene alterations (including point mutations, amplification, and fusion). A number of drugs targeting MET (small molecule TKIs, MET antibody, and HGF antibody) have been studied. MET, c-mesenchymal-epithelial transition factor; HGF, hepatocyte growth factor; NSCLC, non-small cell lung cancer.

MET Exon 14 Skipping Mutations

METex14 alterations (point mutations, deletions, insertions, and complex mutations) lead to decreased degradation of MET receptor, resulting in the activation of MET signaling and the tumorigenesis.^33–36 The evaluation methods for METex14 skipping mutations include differential MET exon expression,^37,38 quantitative reverse transcription-polymerase chain reaction (qRT-PCR)³⁹ or direct RNA sequencing.^37,40 In addition, DNA and RNA sequencing can be used to detect Y1003, a “functional mimetic” of the METex14 skipping mutation, accounting for approximately 2% of all METex14 alterations.⁴¹

In 2015, Frampton et al performed a large-scale molecular profiling of METex14 alterations in 38,028 tumor samples. Of the 221 tumor samples containing METex14 alterations, 193 were found to be lung cancer, of which 131 were lung adenocarcinoma.⁴² METex14 skipping mutations have been reported in 2–4% of NSCLC.^37,43–45 The mutation rate was closely related to the histological subtype of NSCLC, most commonly in sarcomatoid carcinoma (4.9% ~ 31%), followed by adenosquamous carcinoma (5%), adenocarcinoma (3%) and squamous cell carcinoma (2%).^{39,41,46–48} In addition, METex14 mutations are likely to be mutually exclusive of other genetic alterations in NSCLC and are more likely to occur in elderly, non-smoker patients.^39,42 In a study of 933 patients with non-squamous NSCLC, no mutations in the KRAS, EGFR, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), ALK, ROS1, or RET were found in 30 patients with METex14 alterations.³⁹ In 687 Asian patients with NSCLC, METex14 skipping mutations are poor prognostic factors of overall survival.⁴⁹ In NSCLC patients, METex14 skipping mutations are associated with the efficacy of MET protein TKIs, especially in patients with advanced lung sarcomatoid carcinomas.^{38,42,48,50–54}

MET Amplification

MET amplification is the carcinogenic driver. Fluorescence in situ hybridization (FISH) can distinguish between the two based on the ratio of MET/CEP7 (centromeric chromosome 7). In polyploid, each copy of MET is associated with centromeres, and the MET/CEP7 ratio remains constant as the number of copies increases. In MET amplification, the MET/CEP7 ratio increased due to the increased copy number of the MET gene.⁵⁵ Next generation sequencing can also be used to evaluate MET amplification and provide other potentially clinically relevant genomic alteration information.⁵⁶

The MET amplification was reported in 2–5% of NSCLC.^57,58 The high MET gene amplification (MET/CEP7 ≥ 5) is very rare, with an incidence of only 0.34%, and no other oncogenic driver genes were found in these patients compared to patients with low MET gene amplification (MET/CEP7 ratio < 5), which also suggests that high MET gene amplification may act as a carcinogenic driver.⁵⁹ In addition, the incidence of MET amplification was higher in NSCLC patients treated with erlotinib/gefitinib, ranging from 5% to 22%.^31,32,60 MET FISH-positive patients with advanced NSCLC have a poor overall survival.^13,14,61 There is a correlation between high amplification of MET gene and high response rate of crizotinib.⁶² In a Phase I clinical trial (NCT00585195), a patient with advanced lung adenocarcinoma harboring high levels of MET amplification by FISH (MET/CEP7>5), and received crizotinib treatment, obtained a persistent partial response (PR).⁶³ Preliminary results showed that 1 (16.7%) of 6 patients with moderate MET amplification (MET/CEP7 ratio >2.2 to <5) obtained PR; and 3 (50%) of 6 patients with high-level MET amplification (MET/CEP7 ratio >5) obtained PR. No PR was observed in patients with low MET amplification levels (MET/CEP7 ratio 1.8 to 2.2).⁶⁴ Notably, Zhang et al reported a rapid response to crizotinib in a patient with lung adenocarcinoma, which showed an increase in MET copy number but a low MET/CEP7 ratio.⁶⁵ Therefore, larger clinical trials are needed to assess the predictive value of MET gene amplification for targeted therapies.

Impaired MET Receptor Degradation

Impaired MET receptor degradation seems to be a mechanism for ligand-independent aberrant MET signaling.⁶⁶ The HGF/SF binding to MET induces dimerization of the c-MET receptor and activation of downstream signaling pathways. Tyrosine 1003 (Y1003), contained in c-MET juxtamembrane domain encoded by METex14, is a direct binding site for c-Cbl, an E3 ubiquitin ligase. After c-Cbl binds to Y1003, the MET receptor is internalized into endosomes and ubiquitinated, and degraded by the lysosomal pathway.³⁵ However, in NSCLC, nearly all of the METex14 skipping can delete Y1003, c-Cbl binding site, in the juxtamembrane domain.⁴² This leads to MET ubiquitination abrogation, increased MET protein stability, and impaired MET degradation. This induces ligand-independent MET activation.^35,42,66,67 Besides METex14 skipping, mutant cells of Casitas B-lineage lymphoma (CBL), an E3 ubiquitin ligase, show decreased MET ubiquitination, increased MET expression, and higher sensitivity to MET inhibitor SU11274 than CBL wild-type cells, suggesting that CBL status maybe a potential biomarker for MET-targeted therapeutics in NSCLC.⁶⁸

MET Fusion

The MET fusion gene consists of METs that are lacking in juxtamembrane regulatory sequence and different N-terminal partners. The genes that are currently found to be fused with MET include TPR, TRIM4, ZKSCAN1, PPFIB1, LRRFIP1, EPS15, DCTN1, PTPRZ1, NTRK1, CLIP2, TFG, HLA-DRB1, etc. These chimeric proteins are constitutively phosphorylated in a xenograft animal model and induce tumorigenesis.⁶⁹ A case report described a patient with lung cancer with HLA-DRB1-MET fusion who obtained PR for 8 months after receiving crizotinib.⁷⁰ As with the fusions described above, this chimeric MET contains a kinase domain without a juxtamembrane regulatory sequence. Another kinase fusion, KIF5B-MET, was found in a patient with lung adenocarcinoma. This fusion-driven MET activation is probably due to constitutive dimerization and is likely an operational target which can be inhibited by agents. It is similar to other fusions in lung cancer, such as ALK, ROS1, and RET.⁷¹

Overexpression of MET/p-MET

In addition to gene amplification, mutation or fusion, the MET pathway can also activate protein overexpression by upregulating the secretion signal of MET or HGF, inducing tumor transformation.^72,73 The MET overexpression rate in unselected NSCLC ranges from 15% to 70%, which depends on the antibody assay and positive threshold.^10,74–76 In addition to the total level of protein, ligand-activated MET that induces phosphorylation of the juxtamembrane domain can also be detected by phosphorylation-MET (p-MET). Specific expression of p-MET has been observed in approximately two-thirds of lung cancer samples.^10,36 Previous study has reported the expression and prognosis value of MET, p-MET, and HGF in lung cancer patients (n=129).⁷⁷ The high expression of two specific forms of p-MET, cytoplasmic expression of Y1003 (P=0.016; HR =1.86; 95% CI: 1.12–3.07), and nuclear expression of Y1365 (P=0.034; HR=1.70; 95% CI: 1.04–2.78) were negative prognostic factors for overall survival. Thus, the particular type of p-MET may be biomarkers for selecting patients who are likely to benefit from MET inhibitors.

Although the overexpression of MET protein is associated with poor prognosis in lung cancer, it was less effective as a predictive biomarker for targeted therapeutic efficacy.⁷⁸ Previous studies have found that MET overexpression has higher sensitivity and negative predictive value;^49,79 however, due to the significant intratumoral heterogeneity, immunohistochemical evaluation of MET overexpression remains challenging, limiting its use as a biomarker in the clinic.^80,81 This difficulty in screening patients for MET-targeted therapy may also partly explain the failure of MET inhibitors in recent phase III clinical trials of NSCLC.^82,83

Role of MET in Induction of EGFR-TKIs Resistance

MET amplification is a potential resistance pattern of EGFR-TKIs in NSCLC, accounting for 50–60% of the first- and second-generation EGFR-TKIs acquired resistance,^31,32,84 accounting for 15–19% of the third-generation EGFR-TKIs acquired resistance.^85,86 In 2018, ESMO reported two important studies on the mechanisms of acquired resistance to osimertinib.^85,86 FLAURA and AURA2 study provided patients treated with first-line and second-line osimertinib, respectively. Second-generation sequencing was performed on patient plasma samples at disease progression and/or treatment discontinuation. The results showed that MET amplification was the most common acquired resistance mechanism to first-line (15% MET amplification, n=91) and second-line (19% MET amplification, n=73) treatment. In addition, increased circulating levels of HGF in tumor and stromal cells can lead to dysregulation of the MET pathway,^87,88 which can also confer EGFR-TKIs resistance.^87,89 In vitro and in vivo preclinical studies have shown that MET-targeted agents can reverse the resistance to EGFR inhibitors and restore sensitivity in this particular genetic context.^32,90,91

In fact, synergistic effects of epidermal growth factor (EGF) and HGF on cell proliferation have been demonstrated in preclinical studies of NSCLC. When cells are stimulated by HGF and EGF, respectively, an increase in cell wrinkles can be observed, to form on the mobile cell surface. When these growth factors are combined, an additive effect can be observed,⁹² indicating that the combination of MET inhibitors and EGFR-TKIs may have synergistic anti-tumor effects. This provide a theoretical basis for the clinical application of combination targeted therapy in the treatment of patients with NSCLC, especially of patients with EGFR-TKIs resistance.

Therapeutics to Inhibit the HGF/c-Met Axis

Only patients with MET gene alterations may have an objective response (tumor regression) after receiving MET-targeted therapy, whereas targeting the HGF/MET axis in MET wild-type patients has little effect on cancer cell growth or on the efficacy of chemotherapy agents.⁹³ In many cases, MET inhibitors have been reported to be effective in patients with NSCLC, who have high levels of MET amplification^63,64 or METex14 skipping mutations.^{38,42,51,54,94–96} There are a variety of MET inhibitors, including small molecule TKIs and monoclonal antibodies (mAbs) against MET or its ligand HGF, for clinical studies of NSCLC. The results of clinical studies of c-MET inhibitors for NSCLC are shown in Table 1. Table 2 summarizes ongoing clinical studies on c-MET inhibitors for NSCLC.

Table 1.

Results of Clinical Trials with Targeted MET Inhibitors in NSCLC

Agents & Mechanism	Study	phase	Patients	c-MET Alteration	Treatment	No. of Pts	Efficacy Outcome	Status
Crizotinib (PF02341066) Multi-TKIs	NCT00585195 (PROFILE-1001)	1	NSCLC	MET exon 14-altered	Crizotinib	18	ORR: 44% (22–69%) Crizotinib has antitumor activity in patients with MET exon 14-altered NSCLC.	Active, not recruiting
	NCT00585195	1	NSCLC	c-Met-amplification (FISH)	Crizotinib	13	ORR: MET/CEP 7≥1.8: 33% (n=13) 2.2< MET/CEP7<5: 20% (n=6) MET/CEP 7≥5: 50% (n=6)	Active, not recruiting
Cabozantinib (XL184) Multi-TKIs	NCT01866410	2	Pretreated EGFR-mutation NSCLC	None	XL184 + erlotinib	37	ORR: 10.8% (95% CI 0.3–21.3%) PFS: 3.6 (95% CI 2.0–5.6) OS: 13.1 (95% CI 7.1-NA)	Completed
	NCT01708954	2	EGFR wild-type NSCLC	None	Arm A: Erlotinib; Arm B: XL184; Arm C: Erlotinib + XL184	38; 38; 35	Arm A: PFS 1.8 (95% CI 1.7–2.2) Arm B: PFS 4.3 (95% CI 3.6–7.4) P=0.0003 (HR 0.27–0.55) Arm C: PFS 4.7 (95% CI 2.4–7.4) P=0.0003 (HR 0.25–0.53)	Active, not recruiting
	NCT00940225	2	Selected tumour including NSCLC	None	XL184	60	NSCLC: ORR 10%; PFS 4.0	Completed
Foretinib (GSK1363089) Multi-TKIs	NCT01068587	1/2	Pre-treated advanced NSCLC unselected for EGFR genotype	None	Erlotinib ± Foretinib	31	ORR: 17.8% (5/28) Baseline c-Met expression associated with response.	Completed
Tepotinib (EMD1214063) selective-TKIs	NCT02864992 (VISION)	2	Advanced NSCLC	MET Exon 14 skipping	Tepotinib	85	LBx ORR: 51.4% (IR), 63.9% (INV) TBx ORR: 41.5% (IRC), 58.5% (INV)	Recruiting
Capmatinib (INC280, INCB28060) selective-TKIs	NCT01324479	1	Advanced solid tumors including NSCLC	cMET+ (H-score ≥ 150 or cMET/centromere ratio ≥ 2.0 or GCN ≥ 5 or IHC 2+ or 3+)	Capmatinib	43	ORR: 29% (5/17) for MET IHC 3+; 63% (5/8) for cMET GCN ≥ 5; 19% (5/26) for MET+.	Completed
	NCT01610336	2	Previously EGFR-TKI treated EGFR-mut/C-MET amplified NSCLC	MET+ (MET GCN 4 or 50% of tumor cells IHC 3+)	INC280 + gefitinib	83	ORR: 18% (12/65) for total patients 19% (10/53) for HC 2/3+/ GCN ≥5 30% (7/23) for GCN ≥ 6	Active, not recruiting
Tivantinib (ARQ 197) selective-TKI	NCT01395758	2	Local advanced or metastatic NSCLC	None	ARQ197 + erlotinib Pem, Dox, or Gem	51 45	ITT: PFS 7.3vs.18.6, P=0.50 OS 6.8vs.8.5, P=0.44 ORR 0%vs.8.9%	Completed
	NCT01244191	3	Local advanced or metastatic non-squamous NSCLC	MET+ (IHC score≥2 in ≥ 50% tumor cells; FISH GCN>4)	ARQ197 + erlotinib Placebo + erlotinib	526 522	ITT: OS 8.5vs.7.8, P=0.81 PFS 3.6vs.1.9, P<0.001 ORR 10.3% vs 6.5% MET +: OS 9.3vs.5.9, P=0.03 PFS 3.7vs.1.9, P=0.01 Longer OS in patients with tumors with MET GCN >4 (HR 0.83)	Completed
	NCT01580735	2	EGFR mutated, advanced or metastatic NSCLC progressed on EGFR-TKI	MET high (IHC score≥2 in ≥ 50% tumour cells; FISH ≥4 copies/cells)	ARQ197	45	ITT: ORR 6.7% (95% CI 1.4% to 18.3%) PFS 2.7 (95% CI 1.4 to 4.2) OS 18.0 (95% CI 13.4 to 22.2) c-Met high vs low: PFS 4.1 vs 1.4; OS 20.7 vs 13.9	Completed
	NCT00777309	2	Locally advanced or metastatic NSCLC	MET+ (FISH ≥4 copies in ≥40% of cells)	Erlotinib +ARQ197 Erlotinib + placebo	84 83	ITT: PFS 3.8 vs 2.3, P=0.24 OS 8.5 vs 6.9, P=0.47 ORR 10% vs 7%	Completed
	NCT01377376 (ATTENTION)	3	LA or metastatic NSCLC with wild type EGFR	MET (IHC score≥2 in ≥ 50% tumor cells; FISH >4 copies/cells)	ARQ197 + erlotinib Placebo + erlotinib	154 153	ITT: OS 12.7 vs 11.1, P=0.427 PFS 2.9 vs 2.0, P=0.019 Tivantinib was associated with a weak OS benefit in MET IHC+ patient (HR 0.83)	Terminated*
Onartuzumab (MetMab)	NCT00854308 (OAM4558g)	2	Second- or third-line advanced NSCLC	MET+ (IHC score 2+/3+)	Erlotinib+MetMab Erlotinib+placebo	69 68	All: PFS 2.2vs.2.6, P=0.69 OS 8.9vs.7.4, P=0.34 ORR 5.8%vs.4.4%, P=0.71 MET+: PFS 2.9vs.1.5, P=0.04 OS 12.6vs.3.8, P=0.002 ORR 8.6%vs.3.2%, P=0.37	Completed
	NCT01456325	2	Advanced/metastatic NSCLC with MET diagnosis-positive	MET+ (≥50% of cells IHC score 2+ or 3+; FISH≥5 copies/cell)	Erlotinib + placebo Erlotinib+ MetMab	137	OS: FISH+ 2.4vs.11.1, P=0.35 IHC+/ FISH-: 3.7vs.8.7, P = 0.01 High MET mRNA: nonsignificant Low plasma HGF: 6.9vs.10.4, p=0.09	Completed
	NCT01456325 (MetLung)	3	MET-diagnostic NSCLC	MET+ (IHC score 2+/3+; FISH≥5 copies/cell)	MetMab+ erlotinib Placebo + erlotinib	250 249	ITT: OS 6.8vs.9.1, P=0.067 PFS 2.7vs.2.6, P=0.92 ORR 8.4%vs.9.6% There were no statistically significant differences in OS, PFS, or ORR in MET FISH+ patients.	Completed
Emibetuzumab (LY2875358) MetMab	NCT01900652	2	Stage IV NSCLC	MET Dx-high (≥ 60% of cells ≥ 2+); MET Dx+ (IHC ≥ 10% of cells ≥ 2+)	Emibetuzumab; Emibetuzumab + erlotinib	28; 83	MET Dx+ (n=89) ORR: LY+E: 3.0% (95% CI: 0.4+10.5); LY: 4.3% (95% CI: 0.1, 21.9). MET Dx-high (n=74) ORR: LY+E: 3.8%; LY: 4.8%. DCR: LY+E: 50%; LY: 26%. PFS: LY+E: 3.3 (95% CI: 1.7–4.2); LY: 1.6 (95% CI: 1.2–3.1). OS: LY+E: 9.2 (95% CI: 6.7–12.0); LY: 8.2 (95% CI: 3.7–12.6).	Completed
	NCT01897480	2	NSCLC with activating EGFR mutation	MET IHC 3+ expression in ≥90% of tumor cells	Erlotinib; Erlotinib + emibetuzumab	70; 71	PFS for ITT: 9.5 vs 9.3, HR=0.89, 90% CI 0.64–1.23; P=0.534 PFS for MET+ (n=24): PFS 20.7 vs 5.4, HR: 0.39; 90% CI: 0.17–0.91	Active, not recruiting
Rilotumumab (AMG 102) HGBMab	NCT01233687	1/2	Previously treated advanced NSCLC	none	Rilotumumab + Erlotinib	45	DCR: 60% (95% CI: 47–71%) ORR: 8.8% (95% CI: 0.4–18.4%) PFS: 2.6 (95% CI: 1.4–3.3) OS: 6.6 (95% CI: 5.6–8.9)	Completed
Ficlatuzumab HGBMab	NCT01039948	2	Lung adenocarcinoma	MET/HGF expression (IHC)	Ficlatuzumab + gefitinib (G+F) Gefitinib (G)	94 94	G+F: ORR 43% PFS 5.6 for all; 7.4 for MET high G: ORR 40% PFS 4.7 for all; 5.5 for MET high	-

Note: *Enrollment was stopped when 307 patients were randomized, following the Safety Review Committee’s recommendation based on an imbalance in the interstitial lung disease (ILD) incidence between the groups.

Abbreviations: NSCLC, non-small cell lung cancer; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; MET, mesenchymal-epithelial transition factor; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, Fluorescence in situ hybridization; GCN, gene copy number. Pem, Pemetrexed; Dox, docetaxel; Gem, gemcitabine; LBx, liquid biopsy; TBx, tissue biopsy; IRC, independent review committee; INV, Investigator evaluation; LA: local advanced.

Table 2.

Ongoing Clinical Studies with MET Inhibitors in Advanced NSCLC

Agents & mechanism	Clinical Trial	Phase	Patients of Lung Cancer	Design	Endpoints	Status
Crizotinib (PF02341066) Multi-TKIs	NCT00585195 (PROFILE-1001)	1	Advanced malignancies including NSCLC	Crizotinib	Safety	Active, not recruiting
	NCT02465060 (NCI-MATCH)	2	Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma including lung cancer	Crizotinib	Efficacy	Recruiting
	NCT02499614 (METROS)	2	Pretreated Metastatic Non-small-cell Lung Cancer with MET Amplification or ROS1 Translocation	Crizotinib	Efficacy	Recruiting
	NCT02664935 (Matrix)	2	NSCLC	Crizotinib	Efficacy	Recruiting
	NCT01121575	1	NSCLC resistance to erlotinib or gefitinib	Arm1:Dacomitini→Dacomitinib+Crizotinib Arm2: Dacomitinib+Crizotinib	Safety	Completed
	NCT00965731	1	Advanced non-squamous NSCLC	Crizotinib plus erlotinib	Safety	Completed
Cabozantinib (XL-184, BMS-907351) Multi-TKIs	NCT00596648	1b/2	Previously erlotinib treated NSCLC	Cabotinib with or without erlotinib	Safety/efficacy	Completed
	NCT03911193	2	NSCLC with MET deregulation	Cabozantinib	Efficacy	Recruiting
	NCT01639508	2	Advanced NSCLC, ROS1 or NTRK Fusions or Increased MET or AXL Activity	Cabozantinib	Efficacy	Recruiting
	NCT02132598	2	NSCLC with brain metastases	Cabozantinib	Eficacy	Recruiting
	NCT03468985	2	Pre-treated non-squamous NSCLC	Nivolumab; Nivolumab + XL-184; Nivolumab + XL-184 + ipilimumab	Efficacy	Active, not recruiting
Foretinib (GSK1363089) Multi-TKIs	NCT02034097	2	Advanced NSCLC	Foretinib ± erlotinib	Efficacy	Withdrawn
Glesatinib (MGCD265) Multi-TKIs	NCT02954991	2	Advanced NSCLC, previously treated with platinum doublet chemotherapy and a checkpoint inhibitor	Glesatinib + nivolumab	Efficacy	Recruiting
	NCT02544633	2	Locally advanced or metastatic NSCLC with activating genetic alterations in MET, including patients with MET activating mutations in tumor tissue or in blood, and patients with MET gene amplification in tumor tissue or in blood.	Glesatinib	Efficacy	Completed
Mererstinib (LY3164530) Multi-TKIs	NCT02920996	2	NSCLC Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements	Mererstinib	Efficacy	Recruiting
Tepotinib (EMD1214063) selective-TKIs	NCT01982955 (INSIGHT)	1/2	Previously EGFR-TKI treated locally advanced or metastatic EGFR-mutant NSCLC	Tepotinib + gefitinib	Safety/efficacy	Active, not recruiting
	NCT03940703	2	MET Amplified, Advanced or Metastatic NSCLC	Tepotinib + Osimertinib	Safety/efficacy	Not yet recruiting
	NCT02864992 (VISION)	2	Advanced NSCLC with MET Exon 14 skipping alterations or MET amplification	Tepotinib	Efficacy	Recruiting
Savolitinib (AZD6094, Volitinib, HMPL-504) selective-TKIs	NCT02897479	2	NSCLC patients with MET Exon 14 mutation	Savolitinib	Efficacy	Recruiting
	NCT02143466 (TATTON)	1	EGFR mutated advanced NSCLC who have progressed on an EGFR-TKI	Savolitinib + osimertinib	Safety	Active, not recruiting
	NCT02374645	1	EGFR mutated NSCLC who have progressed on EGFR-TKIs	Savolitinib + gefitinib	Safety	Active, not recruiting
	NCT03778229	2	EGFR mutated and MET+ locally advanced or metastatic NSCLC who have progressed on osimertinib	Savolitinib + osimertinib	Efficacy	Recruiting
	NCT03944772 (ORCHARD)	2	Advanced NSCLC who have progressed on osimertinib	Savolitinib + osimertinib	Efficacy	Recruiting
	NCT02117167 (SAFIR02_Lung)	2	Metastatic NSCLC, MET+ evaluated by throughput genome analysis	Savolitinib	Efficacy	Active, not recruiting
Capmatinib (INCB28060) selective-TKIs	NCT03693339	2	NSCLC Harboring MET Exon 14 Skipping Mutation	Capmatinib	Efficacy	Recruiting
	NCT03647488	2	EGFR-wild and ALK-negative NSCLC	INC280+spartalizumab; docetaxel	Safety/efficacy	Recruiting
	NCT03240393	2	Advanced NSCLC	Capmatinib	Efficacy	Withdrawn
	NCT02414139	2	EGFR wild-type, advanced NSCLC	Capmatinib	Efficacy	Recruiting
	NCT02276027	2	Advanced NSCLC with alteration of the c-MET gene	Capmatinib	Efficacy	Active, not recruiting
	NCT02323126	2	c-Met Positive NSCLC	Capmatinib + nivolumab	Efficacy	Recruiting
	NCT02335944	1/2	EGFR-mutant NSCLC	Capmatinib + EGF 816	Safety/efficacy	Active, not recruiting
	NCT01911507	1	C-Met Expressing NSCLC: IHC (2-3+), FISH, RT-PCR	Capmatinib + erlotinib	Safety	Active, not recruiting
	NCT02468661	1	Advanced/Metastatic NSCLC With EGFR Mutation and cMET amplification	Capmatinib ± erlotinib; Platinum + pemetrexed	Safety	Recruiting
	NCT02750215	2	NSCLC with MET Exon 14 Alterations Received Prior MET Inhibitor	Capmatinib	Efficacy	Recruiting
Tivantinib (ARQ 197) selective-TKIs	NCT01069757	1	Advanced/recurrent NSCLC	Tivantinib + erlotinib	Safety	Completed
	NCT01251796	1	Advanced/recurrent NSCLC	Tivantinib + erlotinib		Completed
	NCT02049060	1/2	Advanced/metastatic non-squamous NSCLC Malignant pleural mesothelioma	Tivantinib + carboplatino + pemetrexed	Safety	Unknown
SAR125844 selective-TKIs	NCT02435121	2	Advanced pre-treated NSCLC with MET amplification	SAR125844	Efficacy	Completed
Onartuzumab (MetMAb)	NCT01887886	3	Stage IIIB/IV NSCLC with EGFR mutation and MET positive	Erlotinib + onartuzumab Erlotinib + placebo	Efficacy	Completed
	NCT01519804	2	Incurable stage IIIB or IV squamous NSCLC	Pac/platinum + Onartuzumab Pac/platinum + placebo	Efficacy	Completed
	NCT01496742	2	Stage IIIB/IV non=squamous NSCLC	Onartuzumab + Pac/Pem + Platinum + Bev Placebo + Pac/Pem + Platinum + Bev	Efficacy	Completed
	NCT02031744	3	Second- or third-line treatment for stage IIIB/IV NSCLC patients with MET-positive	Erlotinib + placebo Erlotinib + onartuzumab	Efficacy	Completed
	NCT02044601 (BATTLE-XRT)	1/2	NSCLC	Chemoradiation + onarzumab Chemoradiation + onarzumab + erlotinib	Safety/efficacy	Withdrawn
Telisotuzumab (ABBV 399) MetMab	NCT03574753 (Lung-MAP S1400K)	2	Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer	ABBV-399	Efficacy	Active, not recruiting
JNJ-61186372 EGFR and MET antibody	NCT02609776	1	Advanced NSCLC	JNJ-61186372	Safety	Recruiting
Ficlatuzumab (AV-299) HGBMab	NCT01039948	1b/2	Asian NSCLC patients, unselected for EGFR mutation	Ficlatuzumab + gefitinib	Safety/efficacy	Completed
	NCT02318368	2	Previously untreated, metastases EGFR-mutant NSCLC	erlotinib + Ficlatuzumab Erlotinib + placebo	Safety/efficacy	Terminated

Abbreviations: Bev, Bevacizumab; Pac, Paclitaxel; Pem, Pemetrexed; NSCLC, non-small cell lung cancer; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; LA, local advanced; MET, mesenchymal-epithelial transition factor; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.

Multi-Kinase MET Inhibitors

Crizotinib (PF-02341066)

Crizotinib is an oral multi-target TKI that competes with c-Met tyrosine kinase domain for binding the adenosine triphosphate (ATP) site,³⁰ preventing receptor activation and downstream signaling transmission, as well as competing for ATP binding sites with other kinases, including vascular endothelial growth factor receptor (VEGFR), ROS1, and EML4-ALK, etc.^64,97,98 Crizotinib has been approved by the FDA for patients with advanced NSCLC harboring ALK or ROS1 fusion.^99,100

In PROFILE-1001 study, of 18 patients with NSCLC harbored METex14 skipping mutations who received crizotinib, 8 patients obtained an objective response (44%; 95% CI: 22–69%);⁵⁰ 13 patients with c-MET amplification were divided into low (1.8–2.2), medium (>2.2 - <5), and high (≥5) FISH ratio grades. The results showed that 4 patients obtained an objective response (33%; 95% CI: 10–65%). One of the four was mid-level while three were of high-level amplification group⁶⁴ A multicenter retrospective analysis showed that for patients with METex14 NSCLC, treatment with a MET inhibitor (including crizotinib) is associated with an improvement in overall survival. The median overall survival (mOS) of 34 metastatic patients, who had never received MET inhibitor therapy, was 8.1 months, while mOS of 27 metastatic patients who had received at least one MET inhibitor (including crizotinib, glesatinib, capmatinib, and ABBV-399), was 24.6 months. Treatment with MET inhibitors significantly prolonged these patients’ mOS (HR=0.11; 95% CI: 0.01–0.92; p = 0.04). The median progression-free survival (PFS) of 22 patients receiving crizotinib was 7.36 months.¹⁰¹ In addition, previous studies have also evaluated the efficacy and safety of crizotinib in combination with other targeted therapies in patients with NSCLC, including erlotinib¹⁰² and dacomitinib.¹⁰³ However, combination therapy leads to many adverse events (43% of patients had grade 3 or 4 treatment-related adverse events [AEs]) and the efficacy was poor. With these poor results, there are no plans for further research.

Crizotinib has clinical activity in patients with NSCLC with METex14 and MET amplification (FISH ratio grades > 5), indicating that METex14 evaluated by NGS and MET amplification evaluated by FISH appears to be biomarkers for crizotinib treatment in patients with NSCLC. This needs further confirmation. Besides, due to the adverse effects and limited efficacy, combination of crizotinib with other targeted agents is not recommended.

Cabozantinib (XL-184, BMS-907351)

Cabozantinib is another multi-kinase inhibitor targeting c-Met, VEGFR1, VEGFR2, VEGFR3, RET, TIE2, FLT-3 and KIT, which blocks a variety of precancerous signaling pathways.¹⁰⁴ It has significant oral bioavailability and blood-brain barrier penetration.

A phase I clinical trial analyzed the efficacy and safety of cabozantinib in patients with various solid tumors including NSCLC.¹⁰⁵ The results showed that in NSCLC patients (n=60), the objective response rate was 10%, and the median PFS was 4.0 months. Another study evaluated the efficacy of cabozantinib in combination with erlotinib in patients with EGFR-mutant NSCLC who were resistant to EGFR-TKIs.¹⁰⁶ The results showed that the objective response rate was 10.8% (95% CI 0.3–21.3%), median PFS was 3.6 months (95% CI: 2.0–5.6), and the mOS was 13.1 months (95% CI 7.1-NA). Recently, a randomized Phase II trial evaluated the efficacy of erlotinib monotherapy, cabozantinib monotherapy, and erlotinib, in combination with cabozantinib in patients with EGFR wild-type NSCLC.¹⁰⁷ There were 111 patients (38, 38, 35) included in the preliminary analysis. The results showed a significant improvement in the median PFS between the cabozantinib group (4.3 vs 1.8; HR: 0.39, p = 0.0003) and the combination treatment group (4.7 vs 1.8; HR: 0.37, p = 0.0003) compared with the erlotinib group, with tolerable safety.

In clinical trials related to cabozantinib, MET alterations have not been evaluated, but mainly focused on the EGFR status. The theoretical basis is that MET alterations, especially MET amplification may be a potential acquired resistance mechanism to EGFR-TKIs. All these results indicate that cabozantinib alone or in combination with EGFR-TKIs has a potential research prospect for NSCLC patients with EGFR wild-type or resistance to EGFR-TKIs.

Foretinib (XL-880)

Foretinib is a multi-target kinase inhibitor whose targets include c-Met, ROS-1, RON, VEGFR2, KIT, AXL, TIE2, and PDGFR.¹⁰⁸ It can also block proliferation and anti-angiogenesis. Recently, a Phase I clinical trial evaluated the efficacy and safety of foretinib in combination with erlotinib in patients with advanced NSCLC who progressed after chemotherapy.¹⁰⁸ The results showed that the objective response rate (ORR) of 28 evaluable patients (including wild-type EGFR patients) was 17.8% (5/28). Among the 18 samples, regardless of the EGFR gene status, the baseline MET immunohistochemistry (IHC) expression correlated with the ORR.

MET status evaluated by IHC may be a biomarker for foretinib combined with erlotinib treatment in NSCLC patients who have received chemotherapy. This need further confirmation.

Glesatinib (MGCD265)

Glesatinib (MGCD265) is an oral type II kinase inhibitor targeting c-Met, VEGFR1, VEGFR2, VEGFR3, TIE2, and RON.⁴ In an ongoing phase I study,¹⁰⁹ glesatinib showed initial anti-tumor activity in patients with advanced solid tumors with MET positive or AXL rearrangements. All three NSCLC patients with MET alterations (two METex14 mutations, one gene copy number [GCN] increase) showed significant tumor shrinkage at the first assessment.

For NSCLC patients with METex14, glasetinib has shown very promising prospects in phase I clinical trials. This also indicates that METex14 is a potential biomarker. This need to be further confirmed by larger samples.

Selective MET Inhibitors

Capmatinib (INCB28060)

Capmatinib is a highly selective ATP-competitive c-MET inhibitor. It is 10,000 times more selective for c-Met than other kinases, and can inhibits MET activity at picomolar concentrations.¹¹⁰ A phase I clinical trial have evaluated the efficacy and safety of capmatinib in NSCLC patients with c-MET positive (H-score ≥ 150; or c-MET/centromere ratio ≥ 2.0; or GCN ≥ 5; or IHC 2+ or 3+) and EGFR wild type.¹¹¹ A total of 43 patients were included in the NSCLC expansion group. The results showed that in c-MET-positive, cMET IHC 3+, and cMET GCN ≥ 5 patients, the ORR were 19% (5/26), 29% (5/17), and 63% (5/8), respectively. Another Phase I study evaluated the efficacy and safety of capmatinib as a single-agent therapy in patients with advanced solid tumors (including a group of EGFR wild-type MET+ NSCLC patients; n = 55).¹¹¹ Preliminary antitumor activity was observed in NSCLC patients with high MET gene copy number (GCN ≥ 6; ORR=47%) or MET overexpression (IHC 3+; ORR=24%). A phase II study evaluated the efficacy and safety of a combination of capmatinib and gefitinib in patients with EGFR-mutant NSCLC who progressed after gefitinib treatment.¹¹² The results showed that in 65 evaluable patients, the ORR was 18% and the disease control rate (DCR) was 80%. Patients with MET amplification (GCN ≥ 6) obtained an ORR of up to 30%.

A subgroup of a phase II study evaluated the efficacy of capmatinib in METex14+ and EGFR/ALK-negative NSCLC patients (GEOMETRY mono-1), which included a total of six cohorts. Preliminary results showed that for pre-treatment patients with NSCLC with METex4 skipping mutation (cohort 4), capmatinib has a certain ORR and tolerable toxicity, whereas for newly diagnosed patients (cohort 5b) ORR was higher. In 2019, ASCO reported updated data. As of April 15, 2019, a total of 97 patients (cohort 4: n=69; cohort 5b: n=28) with NSCLC with METex14 skipping mutations were enrolled. The results showed that for patients in cohort 4, the ORR was 40.6% (95% CI: 28.9–53.1%), and the median PFS was 5.42 months (95% CI: 4.17–6.97). For patients in cohort 5b, the ORR was 67.9% (95% CI: 47.6–84.1), and the median PFS was 9.69 months (95% CI: 5.52–13.86). Toxcity was tolerable. In this study, 13 patients had baseline brain metastases, and the intracranial ORR was 54% (7/13), of these, 4 patients achieved complete response (CR); the intracranial DCR was 92% (12/13). The response time of internal lesion was consistent with the response time of the extracranial lesion.

These results indicate that MET amplification and METex14 may be potential biomarkers for the treatment of capmatinib in patients with NSCLC. Capmatinib appears to be more effective in newly diagnosis NSCLC patients with METex14.

Tivantinib (ARQ197)

Tivantinib is a non-ATP competitive c-MET inhibitor. A randomized, double-blind, open-label phase II trial evaluated the efficacy and safety of erlotinib in combination with tivantinib versus erlotinib in combination with placebo in patients with advanced NSCLC. A total of 167 patients were enrolled: the proportion of patients harboring EGFR mutations in the combination and standard treatment groups was 10% and 18%, respectively, and the proportion of patients with MET GCN ≥ 4 was 26% and 26.5%, respectively. Compared to standard treatment group, the combination treatment group had a value-advantaged ORR (10% vs 7%), median PFS (3.8 vs 2.3 months; HR = 0.81; p = 0.24), and mOS (8.5 vs 6.9 months; hazard ratio [HR] = 0.87; p = 0.47), but there was no statistical difference. An exploratory analysis of non-squamous NSCLC showed a benefit trend for PFS (HR = 0.71) and overall survival (HR = 0.72) in the combination group compared with the standard treatment group. Subgroup analysis showed that patients with EGFR wild-type (HR = 0.70), KRAS mutation (HR = 0.76), and MET FISH-positive (>5, HR = 0.45) had an advantage with PFS. In the two groups, both were safely tolerated.¹¹³

The MARQUEE phase III study evaluated the efficacy and safety of erlotinib in combination with tivantinib vs erlotinib in combination with placebo in patients with pre-treated NSCLC.¹¹⁴ A total of 1048 patients were enrolled. Interim analysis showed that combination therapy improved median PFS (3.6 vs 1.9 months; HR-0.74; 95% CI: 0.62–0.89; p < 0.001) but did not improve mOS (8.5 vs 7.8 months; HR=0.98; 95% CI: 0.84–1.15) in intention-to-treat (ITT) patients. Exploratory subgroup analysis showed that the combination therapy prolonged mOS (HR=0.70; 95% CI: 0.49–1.01) in patients with high MET expression (MET GCN ≥ 4). This result was confirmed by a phase III study in Asian patients with previously treated stage IIIB/IV non-squamous NSCLC harboring wild-type EGFR (ATTENTION study).¹¹⁵ This study began enrollment with a target of 460 patients. Due to an imbalance in the incidence of interstitial lung disease (ILD) between the 2 groups, 307 patients with NSCLC were finally randomized to receive either erlotinib in combination with tivantinib or erlotinib in combination with placebo. ILD occurred in 6 patients (0 deaths) and 14 patients (3 deaths) in the placebo and tivantinib group, respectively. In ITT population, compared to placebo group, the tivantinib group had significantly prolonged PFS (2.9 months vs 2.0 months; HR = 0.719; p = 0.019), and had a value-advantaged overall survival (12.7 months and 11.1 months; HR = 0.891; p = 0.427).

These results indicate that for patients with NSCLC, MET amplification evaluated by FISH appears to be a potential biomarker for the treatment of tivantinib in combination of erlotinib.

Savolitinib (Volitinib, AZD6094, HMPL-504)

Savolitinib is a selective small molecule MET inhibitor that blocks c-Met activity in an ATP-dependent way. It has high selectivity for MET.¹¹⁶ A phase II clinical trial evaluated the efficacy and safety of savolitinib in combination with osimertinib in patients with NSCLC with positive T790M mutations resistance to osimertinib.¹¹⁷ Preliminary results showed that of the seven patients who received combination therapy, two obtained PR, with tolerable safety.

Osimertinib combined with savolitinib may be a therapy strategy for patients with NSCLC who are resistant to osimertinib. These may show better clinical efficacy in patients with MET alterations after osimertinib resistance. However, further confirmation is needed.

Tepotinib (EMD1214063)

Tepotinib is an oral, ATP-competitive, highly selective c-MET TKI. Its selectivity to c-Met is 1000 times that of other kinases.¹¹⁸ A phase II study evaluated the efficacy and safety of epotinib in patients with NSCLC harboring METEx14 mutations and EGFR/ALK wild-type. The primary end point was the ORR assessed by the independent review committee (IRC) while the secondary endpoint was ORR and safety evaluated by the investigator (INV). As at the time of the data analysis, 85 patients were enrolled (55 and 52 patients in the liquid biopsy [LBx] and biopsy group [TBx], respectively). Thirty-five patients in the LBx group were evaluated for efficacy, the ORR, evaluated by IRC, was 51.4% and 63.9% evaluated by INV. Forty-one patients in the TBx group underwent efficacy evaluation, the ORR was 41.5% evaluated by IRC and 58.5% evaluated by INV. The toxicity was tolerable.

These results indicate that for patients with NSCLC, METex14 maybe a biomarker for tepotinib treatment.

Anti-MET Antibodies

Onartuzumab (MetMAb)

Onartuzumab is a fully humanized, c-MET monoclonal antibody that blocks the alpha chain binding of the HGF to the c-MET ligand binding domain.¹¹⁹ In a phase II study,¹²⁰ pre-treated NSCLC patients were randomized into two groups, one receiving onartuzumab in combination with erlotinib and the other receiving placebo plus erlotinib. A total of 137 patients were enrolled in this study, of which 26 patients (23%) harbored KRAS mutations while 13 patients (12%) harbored EGFR mutations. The results showed that compared with placebo group, the onartuzumab group showed no prolonged PFS (HR=1.09; P=0.69) and overall survival (HR=0.80; P=0.34) in the ITT population. In MET-positive patients (n=66), PFS (HR=0.53; p = 0.04) and overall survival (HR=0.37; p = 0.002) were significantly prolonged in the onartuzumab group. However, in MET-negative patients (n=62), PFS (HR=1.82, p=0.05) and overall survival (HR=1.78, p=0.16) were poor in the onartuzumab group. MET-positive patients in the placebo group had a worse PFS (HR=1.71; p=0.06) and overall survival (HR=2.61; p=0.004) than MET-negative patients. Thus, in MET-positive people, onartuzumab plus erlotinib can improve PFS and overall survival, while in MET-negative patients, the combination therapy is even worse. Therefore, a larger randomized trial included 499 pre-treated patients with MET-positive NSCLC.¹²¹ They were randomized (1:1) to receive erlotinib in combination with placebo or erlotinib in combination with onartuzumab. The results showed that patients in the onartuzumab group did not have improved overall survival (6.8 vs 9.1 months; HR=1.27; p = 0.067), PFS (2.7 vs 2.6 months; HR=0.99; p=0.92), and overall RR (8.4% vs 9.6%; p = 0.63). The trial has been terminated.

Larger clinical trials have not confirmed better efficacy of onartuzumab combined with erlotinib in patients with MET-positive NSCLC. The screening of biomarkers may need to be explored.

Emibetuzumab (LY2875358)

Emibetuzumab is a c-MET monoclonal antibody that blocks the binding of HGF and c-MET, leading to internalization and degradation of c-MET, and prevention of signal transmission. A phase II clinical trial (NCT01900652) evaluated the efficacy and safety of emibetuzumab with or without erlotinib in patients with MET-positive stage IV NSCLC.¹²² A total of 111 patients were enrolled in this study, of which 28 patients received emibetuzumab monotherapy, and 83 patients received emibetuzumab plus erlotinib. The results showed that in patients with MET Dx+ (≥ 10% of cells ≥ 2+ by IHC, n=89) the ORR of monotherapy group was 4.3% (95% CI: 0.1–21.9%), and the ORR of the combination treatment group was 3.0% (95% CI: 0.4–10.5%). In MET Dx-high population (≥ 60% of cells ≥ 2+; n = 74), the combination treatment group had longer PFS (3.3 vs 1.6 months) and overall survival (9.2 vs 8.2 months), and lower ORR (3.8% vs 4.8%) than the monotherapy group. Another phase II clinical trial (NCT01897480) evaluated the efficacy and safety of erlotinib with or without emibetuzumab in patients with advanced NSCLC harboring EGFR mutations.¹²³ A total of 141 patients were enrolled, of which 71 patients were treated with combination therapy and 70 patients received erlotinib monotherapy. The results showed that in the ITT population, the combination treatment group had advantaged value PFS (9.5 vs 9.3 months; HR=0.89; 90% CI 0.64–1.23; P=0.534), with no statistical difference. Exploratory analysis showed that in patients with MET high expression (≥ 90% of cells MET IHC 3+; n = 24), the combination treatment significantly prolonged PFS (20.7 vs 5.4 months; HR=0.39; 90% CI: 0.17–0.91) compared to emibetuzumab monotherapy. In the rest of the population, PFS was not statistically different (HR=1.1; 90% CI: 0.7–1.7).

These results indicate that MET IHC status may be a potential biomarker for the treatment of emibetuzumab in patients with NSCLC.

Telisotuzumab (ABBV 399)

Telisotuzumab is a novel anti-c-MET antibody drug conjugate that can be coupled to monomethyl staphylococin E (MMAE), which mediates killing requiring a threshold level of c-MET expression.¹²⁴ In a phase I study, 16 patients with MET-positive (IHC H score ≥ 150) NSCLC were treated with ABBV-399.¹²⁵ The results showed that 3 patients (18.8%; 95% CI: 4.1%-45.7%) obtained PR. The median response duration time was 4.8 months, and the median PFS was 5.7 months (95% CI, 1.2–15.4 months). The toxicity was tolerable.

Telisotumumab has certain effect on NSCLC patients with MET IHC positive, further confirmation is needed.

JNJ-61186372

JNJ-372 can block ligand binding by binding to EGFR and MET, promote receptor degradation, and trigger antibody-dependent cytotoxicity in the EGFR mutant (EGFRm) NSCLC model.¹²⁶ A phase I study evaluated the efficacy and safety of JIN-61186372 in patients with advanced NSCLC harboring EGFR mutations. In 2019, ASCO congress reported the interim results. Up to the cut-off data analysis, a total of 116 patients were enrolled in the study, of which 97% harbored EGFR mutations. In 88 evaluable patients, 28% (25/88) achieved PR. In 47 patients who were resistant to third generation EGFR-TKI, 21.3% (10/47) achieved PR (6 confirmed), 4 of whom were C797S, 1 was MET amplification, and 5 had no identifiable EGFR/MET gene alterations. In 20 patients with EGFR 20ins, 30% (6/20) achived PR (3 confirmed). The toxicity was tolerable. Patients with resistance to third generation EGFR-TKI, including C797S, MET amplification, and exon 20ins, all had initial responses, and research on expanded doses are ongoing.

JNJ-61186372 has clinical activity in NSCLC patients who harbor EGFR mutation or who are resistant to the third-generation EGFR-TKI, regardless of whether or not the cause of resistance is due to MET amplification.

Anti-HGF Antibodies

Rilotumumab (AMG-102)

Rilotumumab is a fully humanized IgG2 monoclonal antibody that binds to the HGFβ chain and inhibits HGF binding to c-MET.^127,128 A Phase 1/2 study evaluated the efficacy and safety of rilotumumab in combination with erlotinib in patients with NSCLC regardless of the EGFR status.¹²⁹ In all evaluable patients (n=45), the ORR was 8.8% (90% CI: 0.4–18.4%), the DCR was 60% (95% CI: 47–71%), the median PFS was 2.6 months (90% CI: 1.4–3.3 months) and the mOS was 6.6 months (90% CI: 5.6–8.9 months). For patients with wild-type EGFR (n=33), the DCR was 60.6% (90% CI: 46.3–73.3%), the median PFS was 2.6 months (90% CI: 1.4–2.7 months), and the mOS was 7.0 months (90% CI: 5.6–13.4 months).

The results suggested that blocking HGF combined with EGFR-TKI may increase the efficacy of NSCLC patients with EGFR wild-type.

Ficlatuzumab (AV-299)

Ficlatuzumab is a high-affinity humanized IgG1 monoclonal antibody directed against HGF that inhibits HGF-induced c-MET signaling pathway by blocking HGF/cMET binding.¹³⁰ A randomized phase II clinical trial evaluated the efficacy of gefitinib with or without ficlatuzumab in patients with NSCLC.¹³¹ In the EGFR mutations and low c-MET expression subgroup, patients receiving ficlatuzumab plus gefitinib had an improvement in ORR (41% vs 22%) and median PFS (11 vs 5.5 months). However, in the ITT population, the combination therapy did not significantly improve ORR (40% vs 38%, P=0.77), PFS (5.6 vs 4.7 months, HR=0.94, P=0.67) and overall survival (24.7 vs 21.8 months, HR=0.98, P=0.91) compared with the gefitinib monotherapy group.

Ficlatuzumab plus gefitinib can improve the clinical efficacy in NSCLC patients with EGFR mutations and low c-MET expression, indicating that MET expression maybe a biomarker for the ficlatuzumab treatment.

Immunotherapy

For patients with NSCLC with MET alterations, immunotherapy can be administered after exhaustion of the targeted therapy and chemotherapy. When to start immunotherapy for these patients; however, remains to be explored. A study retrospectively analyzed the clinical activity of immunotherapy in patients with NSCLC with oncogenic driver alterations, including 36 patients with MET alterations (MET amplification n=13, METex14 skipping mutation n=23).¹³² They were all received immunotherapy in different treatment lines. In MET alteration subgroup analysis, ORR, median PFS and OS were 16%, 3.4 months and 18.4 months, respectively. Another study retrospectively included 147 patients to evaluate the PD-L1 expression, tumor mutational burden (TMB), and clinical activity of immunotherapy in patients with METex14 lung cancers. The PD-L1 positive (PD-L1 ≥ 1%) rate was 63% (57/111), while TMB was lower in tumors with METex14 alterations compared with unselected NSCLCs. In 24 patients who received immunotherapy, the ORR was 17%, and the median OS was 18.2 months. The median PFS was 1.9 months for the 21 patients assessable for this end point.¹³³ Therefore, compared with the targeted agents and chemotherapy, immunotherapy had a poor clinical activity in MET alteration patients with NSCLC. Single-agent immunotherapy should not be considered before receiving targeted therapies and chemotherapy. The role of combination treatment (ie immunotherapy and chemotherapy, immunotherapy and targeted therapy, immunotherapy and antiangiogenic agents, or combination immunotherapy) in MET alteration patients with NSCLC need further investigation.

Future Challenges

In recent phase III clinical trials, the efficacy of MET inhibitors to treat NSCLC was disappointed.^114,115,134 Whether the target agents were inhibiting the c-MET receptor itself or inhibiting its ligand HGF, they were not effective as monotherapy for patients with unselected NSCLC. From the current research results, the subgroups of patients with NSCLC harboring MET gene alterations, especially MET amplification or METex14 skipping mutation, respond to MET inhibitors. Therefore, it is important to find appropriate biomarkers for selecting patients. In order to improve the applicability of biomarkers, it is important to set two thresholds that distinguish between MET positive and negative or between high and low HGF, and to choose the appropriate method to achieve this. To solve this problem, there is need for large data analysis for the detection methods and treatment effects, to establish standards that meet the MET activation status, and determine reliable thresholds to achieve effective patient stratification and clinical decision making.

In fact, MET inhibitors cannot block the growth of tumors without MET gene alterations, which does not mean that MET inhibitors are not effective in this case. When MET inhibitors are combined with kinase inhibitors in the upstream or downstream signaling pathways, they can inhibit parallel kinase signaling from other receptors, which may improve the clinical outcomes. However, the toxicity of targeted combination therapies could be considerable. In addition, since MET is related to the properties of activated dendritic cell tolerogenic, MET inhibitors may act synergistically with immunological checkpoint inhibitors such as PD-1 antibodies to restore the immune stimulating microenvironment, and release the tumoricidal activity of cytotoxic T cells. Other combination therapies include HGF/c-Met inhibitors plus inhibitors that inhibit the vitality or function of stromal cells such as tumor-associated fibroblasts, endothelial cells, or macrophages.

Conclusion

The MET/HGF axis is a promising therapeutic target in advanced NSCLC. A variety of MET inhibitors have been developed, some of which have entered phase III clinical trials. However, the results of phase III clinical trials to date have been disappointing. Various mechanisms of MET activation in lung cancer, including MET/HGF overexpression, MET gene alterations (such as mutations, amplification, translocation, or transcriptional disorders), and impaired MET degradation provide a range of potential biomarkers. The challenge now is to use a range of agents currently under development to determine which biomarkers are most likely to select the appropriate patient for MET-targeted therapy.

Disclosure

The authors report no conflicts of interest in this work.